Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG0203 R-CHOP schedule comparison in advanced low-grade B-cell lymphoma
jRCTs031180257Phase 3Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2002
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab in mature B-cell lymphoma and follicular lymphoma (FL) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Complete response rate and Progression-free survival. Started Sep 2002; status: completed.
02
Drugs
rituximab
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)
Beyond the preview
Go deeper on jRCTs031180257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180257.